<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixteen patients (8 female, 8 male) with primary <z:mp ids='MP_0001864'>angiitis</z:mp> of the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> (PACNS), were followed prospectively in a <z:hpo ids='HP_0002633'>vasculitis</z:hpo> clinic </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnosis was by angiography in patients without underlying disease </plain></SENT>
<SENT sid="2" pm="."><plain>Median age at diagnosis was 36.5 years, and median duration of follow-up was 28 months </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003674'>Onset</z:hpo> was <z:hpo ids='HP_0011009'>acute</z:hpo> in 14 patients (88%), with 3.5 weeks (median) from <z:hpo ids='HP_0003674'>onset</z:hpo> symptoms to diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>Three women developed symptoms within 3 weeks postpartum </plain></SENT>
<SENT sid="5" pm="."><plain>The most frequent symptoms were severe <z:hpo ids='HP_0002315'>headaches</z:hpo> (12, 75%), <z:hpo ids='HP_0001297'>stroke</z:hpo> (6, 30%), <z:e sem="disease" ids="C0007787" disease_type="Disease or Syndrome" abbrv="tia|TIA|T.I.A.">transient ischaemic attack</z:e> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) (4, 28%), <z:hpo ids='HP_0001250'>seizures</z:hpo> (7, 44%), visual aberration (3, 19%), and <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (5, 31%) </plain></SENT>
<SENT sid="6" pm="."><plain>Laboratory data included high ESR (2, 13%), leucocytosis (8, 80%), <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (1, 6%), positive antinuclear antibody titre (3, 15%), and high levels of complement (5, 31%) </plain></SENT>
<SENT sid="7" pm="."><plain>Lumbar puncture was performed in 12 patients (75%) </plain></SENT>
<SENT sid="8" pm="."><plain>CSF analysis was abnormal in five patients (42%) </plain></SENT>
<SENT sid="9" pm="."><plain>EEG was abnormal in 5/9 patients </plain></SENT>
<SENT sid="10" pm="."><plain>The major CT/MRI scan findings were cerebral haemorrhage (4, 25%), brain <z:mpath ids='MPATH_124'>infarcts</z:mpath> (5, 31%), brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> (2, 13%) and non-specific lesions (2, 13%) </plain></SENT>
<SENT sid="11" pm="."><plain>Four patients had <z:mpath ids='MPATH_458'>normal</z:mpath> studies </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (CS), and five were treated with oral <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Two patients relapsed despite CS and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> therapy </plain></SENT>
<SENT sid="14" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients are alive, and at the last assessment, eight had a permanent neurological deficit, which included <z:mp ids='MP_0000754'>paresis</z:mp> (3, 19%), neurocognitive abnormalities (2, 13%), <z:hpo ids='HP_0000572'>visual loss</z:hpo> (2, 13%) and <z:hpo ids='HP_0001250'>seizure</z:hpo> activity (5, 31%) </plain></SENT>
<SENT sid="15" pm="."><plain>Our data suggest a non-progressive, non-fatal course in those PACNS patients diagnosed angiographically and treated with CS with or without <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
</text></document>